Stockwinners Market Radar for November 23, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:22 EST Wayfair director Choe acquires 10,000 class A shares - In a regulatory filing, Wayfair director Michael Choe disclosed the purchase of 10,000 class A common shares of the company on November 22 at a price of $258.98 per share.

19:02 EST Hutchmed, AstraZeneca initiate SACHI Phase III trial - Hutchmed (HCM) and AstraZeneca (AZN) have initiated SACHI, a China Phase III study of ORPATHYS, an oral, potent, and highly selective MET tyrosine kinase inhibitor, in combination with AstraZeneca's third-generation, irreversible epidermal growth factor receptor TKI, TAGRISSO. The first patient received their first dose on November 22, 2021. The Phase III trial is a multi-center, open-label, randomized, controlled study in patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer with MET amplification after disease progression on EGFR inhibitor therapy. The study will evaluate the efficacy and safety of ORPATHYS in combination with TAGRISSO, compared to platinum-based doublet-chemotherapy, the standard-of-care treatment option in this setting. The primary endpoint of the study is median progression free survival as assessed by investigators. Other endpoints include median PFS assessed by an independent review committee, median overall survival, objective response rate, duration of response, disease control rate, time to response, and safety. Additional details may be found at clinicaltrials.gov, using identifier NCT05015608.

18:23 EST HP Inc. CEO: We expect the PC business to be strong for the foreseeable future - In an interview on CNBC's Mad Money, Enrique Lores said HP Inc. is seeing strong demand across consumer and commercial clients. The company is designing PCs to improve customer experience and security, he noted. "M&A is an important part of our plan and we will do acquisitions in 2022 to build a growth portfolio," he added.

18:13 EST Samsung to build new $17B semiconductor facility in Taylor, Texas - Samsung announced that it would build a new semiconductor manufacturing facility in Taylor, Texas. The estimated $17B investment in the United States will help boost production of advanced logic semiconductor solutions that power next-generation innovations and technologies, the company said. The new facility will manufacture products based on advanced process technologies for application in areas such as mobile, 5G, high-performance computing and artificial intelligence. "As we add a new facility in Taylor, Samsung is laying the groundwork for another important chapter in our future," said Kinam Kim, Vice Chairman and CEO, Samsung Electronics Device Solutions Division. "With greater manufacturing capacity, we will be able to better serve the needs of our customers and contribute to the stability of the global semiconductor supply chain." Groundbreaking will be in the first half of 2022 with the target of having the facility operational in the second half of 2024. The Taylor site will span more than 5M square meters and is expected to serve as a key location for Samsung's global semiconductor manufacturing capacity along with its latest new production line in Pyeongtaek, South Korea. The total expected investment of $17B, including buildings, property improvements, machinery and equipment, will mark the largest-ever investment made by Samsung in the U.S. This will also bring Samsung's total investment in the U.S. to more than $47B since beginning operations in the country in 1978, where the company now has over 20,000 employees across the country. This latest expansion of Samsung's U.S. presence is expected to create over 2,000 high-tech jobs directly and thousands of related jobs once the new facility is in full operation, the company said.

17:22 EST SAIC awarded $123.68M Navy contract - SAIC was awarded a $123.68M fixed-price incentive, firm-fixed-price and cost-plus-fixed-fee contract for the production of MK 48 Mod 7 heavyweight afterbody/tailcones and warshot fuel tank torpedo equipment and support. This contract includes options, which, if exercised, would bring the cumulative value of this contract to $1.11B. This contract combines purchases for the Navy and the governments of Australia and Taiwan under the Foreign Military Sales, or FMS, program. Work is expected to be complete by July 2025. If all options are exercised, work will continue through January 2033. FY21 weapons procurement funds in the amount of $96.97M and FMS/Armaments Cooperative Program funds in the amount of $22.55M, will be obligated at time of award, not to expire at the end of the current fiscal year. This contract was competitively procured via the beta.sam.gov website, with one offer received. The Naval Sea Systems Command is the contracting activity.

17:17 EST HP Enterprise, Dell, IBM and others to compete for orders on $1.6B Army contract - HP Enterprise (HPE), Dell (DELL), IBM (IBM), CDW (CDW) and others will compete for each order of the $1.6B firm-fixed-price contract for commercial hardware, software, and related incidental services at the enterprise level for the Army, Department of Defense, and all other federal clients. Bids were solicited via the internet with 50 received. Work locations and funding will be determined with each order, with an estimated completion date of August 22, 2023. U.S. Army Contracting Command is the contracting activity.

17:00 EST BeiGene announces approval of Brukinsa in EU - BeiGene announced that the European Commission approved BRUKINSA for the treatment of adult patients with Waldenstrom's macroglobulinemia who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy. The approval is applicable to all 27 European Union member states, plus Iceland and Norway. BeiGene is working to make this new treatment option available to WM patients in the EU as quickly as possible. "BTK inhibition is an established mode of treatment for patients with WM, and the approval of BRUKINSA provides an important new option for patients with WM that may offer improved outcomes," said Prof. Christian Buske, Medical Director at the University Hospital Ulm, Germany, and a trial investigator of the ASPEN study. "Patients and their physicians in the EU will soon have access to an innovative medicine that has potential to offer deep and durable responses and improved tolerability, as seen in the ASPEN trial."

16:52 EST FDA approves Takeda's Livtencity for post-transplant CMV - The U.S. Food and Drug Administration approved Livtencity, maribavir, as the first drug for treating adults and pediatric patients with post-transplant cytomegalovirus or CMV, infection/disease that does not respon to available antiviral treatment for CMV. Livtencity works by preventing the activity of human cytomegalovirus enzyme pUL97, thus blocking virus replication. "Transplant recipients are at a much greater risk for complications and death when faced with a cytomegalovirus infection," said John Farley, M.D., M.P.H., director of the Office of Infectious Diseases in the FDA's Center for Drug Evaluation and Research. "Cytomegalovirus infections that are resistant or do not respond to available drugs are of even greater concern. Today's approval helps meet a significant unmet medical need by providing a treatment option for this patient population." CMV is a type of herpes virus that commonly causes infection in patients after a stem cell or organ transplant. CMV infection can lead to CMV disease and have a major negative impact on transplant recipients, including loss of the transplanted organ and death. Livtencity's safety and efficacy were evaluated in a Phase 3, multicenter, open-label, active-controlled trial that compared Livtencity with a treatment assigned by a researcher running the study, which could include one or two of the following antivirals used to treat CMV: ganciclovir, valganciclovir, foscarnet or cidofovir. In the study, 352 transplant recipients with CMV infections who did not respond to treatment randomly received Livtencity or treatment assigned by a researcher for up to eight weeks. Reference Link

16:40 EST Hasbro VP Courtney sells over $1.5M in company shares - Hasbro VP Thomas Courtney disclosed in a filing that he had sold 15,686 shares of company stock at $100.22 per share between Novemebr 19 and November 23 for a total transaction amount of $1,572,027.

16:36 EST Raymond James reports October clients assets under administration up 33% - Raymond James Financial reported selected operating data for October, in an effort to provide timely information to investors about general trends in our major business segments. Due to the limited nature of this data, a consistent correlation to earnings should not be assumed. Record client assets under administration of $1.23T increased 33% over October 2020 and 4% over September. Record financial assets under management of $199.3B increased 32% over October 2020 and 4% over September. The increase of client assets was driven by equity market appreciation and the net addition of financial advisors in the Private Client Group. Record net loans at Raymond James Bank of $25.4B increased 18% over October 2020 and 2% over September. Record clients' domestic cash sweep balances of $66.8B increased 17% over October 2020 and were flat compared to September.

16:32 EST GlycoMimetics says Apollomics doses first patient in Ph3 APL-106 trial in China - GlycoMimetics announced that Apollomics has dosed the first patient in China in a Phase 3 clinical trial of APL-106 for the treatment of adults with relapsed or refractory acute myeloid leukemia. Apollomics' Phase 3 trial with APL-106 is part of the overall development program for Apollomics in China that also includes an ongoing Phase 1 pharmacokinetics and tolerability study. The Phase 3 clinical trial is part of a randomized, double-blind, placebo controlled, bridging study program that will evaluate the efficacy of uproleselan in combination with chemotherapy, compared to chemotherapy alone, for treating relapsed/refractory AML, in Chinese patients. The trial will enroll approximately 140 adult patients with primary refractory AML or relapsed AML and eligible to receive induction chemotherapy. "Dosing of the first patient in this Phase 3 clinical trial in Greater China is a significant accomplishment for Apollomics and comes quickly on the heels of our recent completion of enrollment in our own pivotal Phase 3 trial evaluating uproleselan in addition to a standard chemotherapy regimen in patients with relapsed/refractory AML," commented Harout Semerjian, GlycoMimetics Chief Executive Officer. The primary endpoint for the Apollomics Phase 3 trial is overall survival. Secondary outcome measures include the rate and duration of remission, and whether uproleselan could reduce the rate of oral mucositis, a chemotherapy-related side effect. Apollomics expects to conduct this study at approximately 20 blood cancer clinical research centers across China.

16:28 EST Dell Technologies reports Q3 net cash from operating activities $3.3B - Q3 adjusted EBITDA was $3.4B.

16:26 EST Dell Technologies reports more than $13B in cash flow from operations in Q3 - "We continue to deliver strong results, with more than $13 billion in cash flow from operations on a trailing-twelve-month basis," said Tom Sweet, CFO, Dell Technologies. "The digital trends are tailwinds for our business, and along with our strategy and financial flexibility, lead us to be optimistic about our long-term growth prospects."

16:22 EST Pure Storage jumps 11% to $30.34 after Q3 results, FY22 guidance beat estimates

16:21 EST Gap slips 11% to under $21 after Q3 earnings miss, guidance cut

16:19 EST Gap CFO says operating margin on track to hit 10% by 2023 - "While there is still hard work ahead to navigate near-term challenges in the macro environment, the team has made tremendous progress, adapting quickly while never taking their focus off of our long-term objectives," said Katrina O'Connell, Executive Vice President and Chief Financial Officer, Gap Inc. "We have strong demand for our brands and our fleet rationalization and divestitures are progressing well and adding value. Our operating margin remains on track to hit 10% by 2023, in line with our plan, even as we navigate these near-term disruptions. While our mitigation efforts are driving significant transitory costs, we view these as investments in preserving market share and driving overall health and relevance for our brands."

16:19 EST Allied Esports says party to non-binding LOI discontinuing talks on esports sale - In a regulatory filing, Allied Esports Entertainment disclosed that on November 23, the potential acquiror of the esports operations of the company, who is a party to a non-binding letter of intent with the company, informed the company that it is discontinuing discussions towards the proposed sale of the company's esports business at this time. "In light of this development, the company is resuming conversations with other interested parties and intends to provide an update to stockholders at an appropriate time," Allied Esports stated.

16:17 EST Diodes officer Chen sells over $440K in shares - Diodes officer C.H. Chen disclosed in a filing that he had sold 4,000 shares of company stock at $110.30 per share on November 19, for a total transaction amount of $441,200.

16:16 EST LiqTech appoints Simon Stadil as CFO - LiqTech International announced the appointment of Simon Stadil as its CFO, effective November 22. Claus Toftegaard, most recently LiqTech's CFO, takes over the newly created position of Project Director overseeing the Company's projects in China and Denmark. Stadil comes to LiqTech from Welltec, an international provider of robotic well solutions for the oil and gas industry with approximately $300M in annual revenue, where he served as Director of Treasury & Investor Relations, Regional CFO Americas and Africa, and most recently as Vice President of Global Finance. Additionally, Stadil served as Assistant Funding Manager within the Danish renewable & utility company Orsted, as well as Assistant Vice President within the Nordic Investment Banking Division at Barclays Capital in London.

16:14 EST P&G recalls certain Old Spice, Secret products over benzene detection - The Procter & Gamble Company is voluntarily recalling all lots with expiry through September 2023 of specific Old Spice and Secret aerosol spray antiperspirants and Old Spice Below Deck aerosol spray products sold in the United States and Canada, to the consumer level due to the presence of benzene detected. Benzene is classified as a human carcinogen. Exposure to benzene can occur by inhalation, orally, and through the skin and it can result in cancers including leukemia and blood cancer of the bone marrow and blood disorders which can be life-threatening. Based on exposure modeling and the cancer risk assessments published by the Environmental Protection Agency, daily exposure to benzene in the recalled products at the levels detected in the company's testing would not be expected to cause adverse health consequences. Benzene is ubiquitous in the environment. Humans around the world have daily exposures to it indoors and outdoors from multiple sources. To date, The Procter & Gamble Company has not received any reports of adverse events related to this recall and is conducting this recall out of an abundance of caution. The affected products are used as antiperspirants and hygiene products and are packaged in aerosol cans. The recalled products were distributed nationwide in the United States through retail outlets and online. All other Old Spice and Secret products are not impacted by this issue and may continue to be used as intended. This represents the vast majority of the company's products, including body spray products, solid sticks, soft solids and gel antiperspirants and deodorant products. The Procter & Gamble Company has notified its retailers to remove products from shelves. Old Spice and Secret will also offer reimbursement for consumers who have purchased products impacted by this recall. Consumers should stop using and appropriately discard the affected aerosol spray products.

16:13 EST Dorchester Minerals in non-taxable contribution and exchange agreement - Dorchester Minerals announced that it has entered into a non-taxable contribution and exchange agreement with an unrelated third party to acquire mineral and royalty interests representing approximately 4,600 net royalty acres located in 27 counties across New Mexico, Oklahoma, Texas and Wyoming. The contributing entity will convey its interests to the Partnership in exchange for 1,580,000 common limited partnership units of the Partnership. The acquisition is expected to close on December 31 subject to customary closing conditions, with a cash receipt reference date of October 1.

16:11 EST Puma Biotechnology says USPTO extends patent term for Nerlynx - Puma Biotechnology announced that the United States Patent and Trademark Office issued a Patent Term Extension Certificate for U.S. Patent No. 7,399,865, extending the patent term five years. The patent includes composition of matter claims for NERLYNX and will now expire on December 29, 2030. The patent term extension is pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, also referred to as the Hatch-Waxman Amendments, which permits an extension of the term of one patent for a maximum period of five years. "We are very pleased to have the patent term for NERLYNX extended to 2030. This will allow us to invest further in the drug to look at additional ways that the drug can continue to help cancer patients," said Alan H. Auerbach, Chief Executive Officer and President of Puma.

16:09 EST Autodesk CFO says supply chain disruption 'impacting the pace of our recovery' - "Our customers continue to embrace and prioritize digital transformation to drive growth, efficiency and sustainability, generating strong demand for Autodesk's platform," said Andrew Anagnost, Autodesk president and CEO. "We are rapidly innovating and optimizing our business to enable more customers to experience our ecosystem, and realize the opportunities ahead." "Demand was robust in Q3, driving strong new subscriptions growth and renewal rates. We expect it to remain so in Q4," said Debbie Clifford, Autodesk CFO. "However, supply chain disruption and resulting inflationary pressures, a global labor shortage, and the ebb and flow of COVID, are impacting the pace of our recovery and outlook."

16:05 EST Hingham boosts dividend 4% to 55c per share,declares special dividend - Hingham Institution announced that its Board of Directors has declared a regular quarterly cash dividend of $0.55 per share. This represents an increase of 4% over the previous regular quarterly dividend of $0.53 per share. The dividend will be paid on January 12 to stockholders of record as of January 3. In addition to the regular quarterly dividend, the Bank's Board of Directors announced that it will pay a special dividend of $0.75 per share. This special dividend will also be paid on January 12 to stockholders of record as of January 3, . In November 2020, the Bank declared a special dividend of $0.70 per share.

16:00 EST Esperion trading resumes

15:38 EST Rocket Lab confirms will attempt to catch returning rocket booster mid-air - Rocket Lab confirmed it will attempt to catch a returning rocket booster mid-air with a helicopter during the company's next recovery mission. Rocket Lab's next recovery mission is currently scheduled for the first half of the year, 2022. "The confirmation follows the successful demonstration of helicopter shadow operations for the first time during the company's 22nd Electron launch last week in the company's latest effort to make Electron the world's first reusable, orbital-class commercial small rocket," Rocket Lab said. Rocket Lab CEO, Peter Beck, added: "As one of only two launch companies to repeatedly recover orbital-class boosters from space, we're ready to take the final step and begin collecting them mid-air with a helicopter to race us closer to launch, catch, repeat with the world's first reusable, orbital-class commercial small rocket. A reusable Electron means more rockets and launch opportunities for better access to space for satellite customers, and I'm proud of the Rocket Lab team for continuously pushing the industry forward as the leaders in dedicated small launch."

15:02 EST Meta's Jason Rubin says 'Resident Evil 4 VR' fastest-selling Quest app ever - Jason Rubin, VP of Play at Facebook (FB)/Meta (MVRS), said that Capcom's (CCOEY) "Resident Evil 4 VR" is officially the fastest-selling app in the history of the Oculus Quest brand. "We knew Resident Evil 4 would bring a different kind of thrill in VR, both for diehard fans of the franchise and those new to the game and VR," Rubin said. "I'm excited to share that RE4 is officially the fastest-selling app in the history of Quest." The executive added that "RE4: Mercenaries" DLC will come out next year. Reference Link

14:29 EST Walmart to appeal 'flawed' opioid verdict in Ohio - Walmart issued a statement after an Ohio jury found the company liability of opioids prescriptions: "We will appeal this flawed verdict, which is a reflection of a trial that was engineered to favor the plaintiffs' attorneys and was riddled with remarkable legal and factual mistakes. Among the many problems during this trial, the judge allowed it to continue after a juror violated court rules by conducting her own research and sharing it with other jurors. The judge even said that in his 22 years on the bench he had never seen a juror do "anything like" this, and we agree with the plaintiffs' own lawyer, when he said it was his "ethical obligation" to call for a mistrial because of this juror misconduct. Additionally, this verdict is out of step with courts around the country that have rejected plaintiffs' novel "public nuisance" liability theories in opioid lawsuits in Connecticut, Delaware, Illinois, California, Oklahoma, North Dakota, and South Dakota, to name a few." Reference Link

13:17 EST Griffon confirms receipt of director nominations from Voss Capital - Griffon Corporation confirmed that Voss Capital, LLC, a new 2% shareholder of the company, has provided notice of its intent to nominate three individuals to stand for election to the Griffon Board of Directors at the 2022 Annual Meeting of Shareholders, currently scheduled for February 17, 2022. Griffon issued a statement that said in part: "The Board and management team are committed to acting in the best interest of all shareholders. We have carefully reviewed Voss' assessments and have concluded they are inaccurate. We have been, and will continue to be, proactive in making the decisions to propel the company forward, including the execution of a successful M&A strategy that has allowed for optimal capital redeployment and significant return of capital to shareholders. We intend to continue executing on our strategy to reposition Griffon including through transactions such as the ongoing strategic alternatives review of Telephonics Corporation. We have engaged in good faith with Voss to date. Independent members of the Board have met with them and are currently assessing their nominees in accordance with our thorough process. While we are disappointed by Voss' decision to create public disruption, and despite their misleading statements, we remain open to engaging with them. We have always welcomed constructive dialogue with our shareholders and remain committed to creating shareholder value as well as acting in the best interest of all shareholders."

13:02 EST Apple files lawsuit against NSO Group over surveillance, targeting users - Apple filed a lawsuit against NSO Group and its parent company to hold it accountable for the surveillance and targeting of Apple users. The company said, :The complaint provides new information on how NSO Group infected victims' devices with its Pegasus spyware. To prevent further abuse and harm to its users, Apple is also seeking a permanent injunction to ban NSO Group from using any Apple software, services, or devices. NSO Group creates sophisticated, state-sponsored surveillance technology that allows its highly targeted spyware to surveil its victims. These attacks are only aimed at a very small number of users, and they impact people across multiple platforms, including iOS and Android. Researchers and journalists have publicly documented a history of this spyware being abused to target journalists, activists, dissidents, academics, and government officials."

12:50 EST Valneva jumps 6% to $47.97 after signing Covid vaccine purchase agreement

12:39 EST Epic Games acquires Harmonix, terms not disclosed - Epic Games announced that it has acquired Harmonix, a game development studio known for the "Rock Band" and "Dance Central" franchises. "Harmonix has a track record of creating fun and engaging music experiences designed for everyone to enjoy," Epic said. "As we work to build the metaverse, this expertise is needed to reimagine how music is experienced, created and distributed. The Harmonix team will collaborate closely with Epic to develop musical journeys and gameplay for Fortnite while continuing to support existing titles including Rock Band 4." Investors in Epic Games include Tencent (TCEHY), KKR (KKR), Disney (DIS), and Sony (SONY).

12:00 EST Abercrombie & Fitch falls -16.3% - Abercrombie & Fitch is down -16.3%, or -$7.66 to $39.38.

12:00 EST Peabody Energy rises 10.4% - Peabody Energy is up 10.4%, or $1.10 to $11.73.

12:00 EST Sunlands Online rises 16.9% - Sunlands Online is up 16.9%, or 62c to $4.28.

11:31 EST Activision Blizzard board forms 'Workplace Responsibility Committee' - Activision Blizzard's board of directors last night announced that it has formed a "Workplace Responsibility Committee," initially comprised of two independent directors, to oversee the company's progress in successfully implementing its new policies, procedures, and commitments to improve workplace culture and eliminate all forms of harassment and discrimination at the company. The Committee is being chaired by Dawn Ostroff, an independent director since 2020. Reveta Bowers, an independent director since 2018, will serve on the Committee. In addition, the Company is working to add a new, diverse director to the Board. The Committee will require management to develop key performance indicators and/or other means to measure progress and ensure accountability. The Chief Executive Officer, Bobby Kotick, along with the Chief People Officer and Chief Compliance Officer will provide frequent progress reports to the Committee, which will regularly brief the full Board. The Committee is empowered to retain outside consultants or advisers, including independent legal counsel, to assist in its work. "The Activision Blizzard Board is committed to ensuring a healthy workplace in which all employees feel valued, safe, and respected," the game maker said. "Our Audit Committee has been kept apprised of developments, including the EEOC and DFEH investigations. The Board supports the numerous steps taken by management since 2018 to improve workplace culture, including centralizing the human resources function in 2019 to ensure greater consistency and accountability, strengthening and increasing training, and, most recently, improving methods for reporting and responding to complaints of harassment, discrimination, and retaliation. Beginning in October, the Board has been meeting bi-weekly for in-depth assessments on related plans and progress and also now receives detailed written weekly reports. The Board remains committed to helping drive significant, additional improvements." Reference Link

11:15 EST Churchill Downs sells 115.7 acres near Calder Casino for $291M - Churchill Downs last night announced that the company has signed an agreement to sell 115.7 acres of land near Calder Casino for $291M. Churchill Downs has agreed to sell the land to Link Logistics, an owner of logistics real estate assets, established in 2019 by Blackstone (BX). The closing of the sale of the property is subject to the satisfaction of various closing conditions. The company anticipates closing the sale of the property in the first half of 2022. Churchill Downs is planning to use certain proceeds of the sale to purchase or invest in replacement property "that qualifies as an Internal Revenue Code Section1031 transaction." Following the closing of the transaction, Churchill Downs will retain ownership of approximately 54 acres of the current 170-acre parcel of land on which the company's wholly-owned wholly-owned Calder Casino sits

11:01 EST Dick's Sporting has been 'less promotional' in Q4, says CEO

10:50 EST Dick's Sporting 'much more confident' in outlook than three months ago, says CEO - Comments taken from Q3 earnings conference call.

10:30 EST SPX Flow up 3% in early trading to $83.96 - Early strength in SPX Flow may be related to a report from M&A focused news site CTFN, contacts tell The Fly. Reference Link

10:00 EST Abercrombie & Fitch falls -14.9% - Abercrombie & Fitch is down -14.9%, or -$7.00 to $40.04.

10:00 EST Dycom rises 13.1% - Dycom is up 13.1%, or $10.98 to $94.48.

10:00 EST XL Fleet rises 34.9% - XL Fleet is up 34.9%, or $1.62 to $6.26.

09:47 EST Turkcell falls -9.5% - Turkcell is down -9.5%, or -38c to $3.64.

09:47 EST Best Buy falls -14.6% - Best Buy is down -14.6%, or -$20.12 to $117.88.

09:47 EST Sunlands Online rises 12.6% - Sunlands Online is up 12.6%, or 46c to $4.12.

09:45 EST Gracell Biotechnologies Inc (ADS) trading resumes

09:32 EST Papa John's partners with Kitchen Express to expand into Kenya, Uganda - Papa John's International announced its expansion into Sub-Saharan Africa with its newest franchise partner Kitchen Express LTD, a subsidiary of AAH Limited, the majority shareholder of Hass Petroleum Group, which holds a significant retail footprint in Africa. Kitchen Express LTD plans to open 60 restaurants in Kenya and Uganda, with four of these restaurants planned to open in 2022, beginning in Nairobi. The partnership will enable Hass Petroleum to leverage its significant retail footprint as it introduces new customers to the Papa Johns brand. Kitchen Express LTD, which now holds master franchise rights for the Papa Johns brand in Kenya and Uganda, is an affiliate of Hass Petroleum Group, one of the leading indigenous oil marketing companies in Africa, which currently operates more than 140 petrol stations across 10 countries in Africa.

09:30 EST MyMD Pharmaceuticals issued MYMD-1 patent by USPTO - MyMD Pharmaceuticals announced that the U.S. Patent and Trademark Office, or USPTO, issued U.S. Patent 11,179,382 B2, titled "Methods of Reversing Normal Aging Process and Extending Lifespan." The allowed claims protect the use of MYMD-1 in a method designed to extend the lifespan of an individual.

09:25 EST Merit Medical announces agreement in principle to settle class action suit - Merit Medical Systems announced that it has reached an agreement in principle to settle the securities class action lawsuit against Merit and its Chief Executive Officer and Chief Financial Officer currently pending in the United States District Court for the Central District of California. The lawsuit was filed in June 2020 after Merit's stock price declined following disclosures made by Merit with respect to its operating and financial performance during 2019. The settlement was reached following a voluntary mediation process. The proposed settlement calls for a payment of $18.25 million in resolution of all claims asserted against Merit and all other defendants. Approximately $8.5 million of the settlement payment is expected to be satisfied with proceeds of available insurance. Merit anticipates that the settlement will also provide a full release of all claims against all defendants, including Merit and its officers, and will contain no admission of liability, wrongdoing or responsibility by any of the defendants. The settlement remains subject to final documentation and approval by the court and is subject to satisfaction of customary conditions to effectiveness. A final non-appealable closure of the litigation could take several months.

09:20 EST Exela selected as potential supplier for UK NHS London Procurement Partnership - Exela Technologies has been selected by the UK's National Health Service London Procurement Partnership as a potential supplier. 46 companies were chosen across a spectrum of services, while Exela was chosen for bulk scanning, contact center/help desk and digital mailroom. The Digital Document Solutions Framework is a four-year contract and has a potential total value of GBP 5bn or ~$7bn across all suppliers.

09:18 EST HUMBL launches HUMBL Pay mobile wallet - HUMBL announced the newest release of the "HUMBL Pay" mobile wallet, including the latest upgrades to its Peer-to-Peer functionalities, and additional features that simplify the management of digital assets and blockchain functionality. Under this release, which is now available on the Apple App Store and Google Play Store, HUMBL Pay users can: Buy digital assets via major credit cards inside the HUMBL Pay mobile wallet; Send digital assets such as BTC, ETH and USDC between HUMBL mobile wallets; Perform gasless digital asset transactions between HUMBL mobile wallets; Earn as much as 7% interest on various digital assets. The HUMBL Pay mobile wallet accommodates the purchase of digital assets by credit card, as well as the send and receipt of such digital assets from other users of the HUMBL Pay mobile wallet. Now, the HUMBL Pay user can perform gasless P2P transactions across various digital assets such as Bitcoin, Ethereum and USDC. The HUMBL technology team is also working to accommodate P2P transactions across major government-issued fiat currencies, such as the US Dollar and additional blockchain-authenticated integrations.

09:11 EST Philips launches new AI-enabled MR portfolio at RSNA 2021 - Royal Philips announced new AI-enabled innovations in MR imaging launching at the Radiological Society of North America, RSNA, annual meeting. Philips' new MR portfolio of intelligent integrated solutions is designed to speed up MR exams, streamline workflows, optimize diagnostic quality, and ensure the efficiency and sustainability of radiology operations. Philips' new MR 5300 system being introduced for the first time at RSNA 2021, has received 510(k) clearance from the U.S. Food and Drug Administration. With this introduction, the company's latest BlueSeal fully-sealed helium-free in operations MR scanner continues the advancement of a full helium-free operating portfolio of Philips MR solutions. Powered by AI, the MR 5300 simplifies and automates complex clinical and operational tasks for outpatient clinical use and MR departments to help increase access to affordable, quality care. "The MR 5300's large field-of-view provides extended anatomical coverage, while its robust AI-powered scanning methods and easily positioned ultra-lightweight dStream Breeze coils work together to generate exceptional image quality, especially when imaging challenging anatomies such as the spine and abdomen," the company said. Also debuting at RSNA 2021, Philips' new MR Workspace with AI assistance is designed to simplify the path from image acquisition to diagnosis and empower technologists to drive productivity and predictability. MR Workspace's intuitive dashboard fully automates the planning and execution of many routine scans and eliminates guesswork by suggesting the most suitable Exam Card for each patient to ensure consistency in radiology department operations. Another major reveal at RSNA 2021 is Philips' new MR 7700 system integrated with multinuclear clinical capabilities to give clinical researchers the confidence to explore new imaging pathways. Researchers can also leverage the accuracy, power, and endurance of the MR 7700's XP gradients to facilitate demanding research programs to boost neuroscience excellence. At RSNA 2021, Philips is also launching its new SmartSpeed reconstruction platform, designed to support the latest AI innovations. The platform is the next big advance on Philips' existing Compressed SENSE acceleration technology, further enhancing the ability to reconstruct a full image from under-sampled data while maintaining virtually equivalent image quality.

09:08 EST SiTime to be added to S&P MidCap 400 Index - SiTime Corporation announced the company will be added to the S&P MidCap 400(R) Index, effective prior to the opening of trading on Tuesday, November 30, 2021

09:07 EST Comtech announces $1.3M contract renewal with a U.S. mobile network operator - Comtech Telecommunication announced , that during its first quarter of fiscal 2022, it was awarded a $1.3M contract renewal with a U.S. tier-one mobile network operator for precise location services.

09:05 EST Usio announces closing of $1M investment by Voyager Digital - Usio announced the closing of a private placement of 142,857 shares of common stock, at a purchase price of $7.00, for net proceeds of $1 million. The shares were priced using a five-day weighted average at the market price with November 19th as the closing date. Usio intends to use the proceeds from the placement for working capital.

09:05 EST Gracell's senior management team members announce share purchase plan - Gracell Biotechnologies announced that members of its senior management team, including its Chairman of Board and CEO William Cao, CFO Yili Kevin Xie and Chief Medical Officer Martina A. Sersch, have informed the Company of their intention to use their personal funds to purchase the Company's American depositary shares, or ADSs, on the open market for an aggregate amount up to a maximum of $2M within the next three months.

09:02 EST authID.ai appoints Christabel Bugla as VP, customer success - authID.ai announced new hires and appointments as the company enters a new phase of growth across industries and geographies. The new appointments reflect an ongoing expansion of the company's global team in line with its core value creation strategies. In doing so, the Company has substantially diversified its management team and broader workforce, nearly half of whom are people of color and/or women. To oversee the expansion of the Company's customer network, Christabel Bugla has been named Vice President of Customer Success. In her new role, Bugla will manage customer experience enhancements, from onboarding to full engagement. Previously, Bugla was Director of Customer Success at Prove, a mobile identity provider, and held senior account management roles at identity verification companies Socure and Jumio. In addition, Brittney Liburd has joined the company as Senior Product Marketing Manager. She brings with her more than a decade of experience supporting robust marketing programs for global identity authentication, network security, and data and analytics providers. Liburd will help authID.ai deliver next-generation cybersecurity technologies to businesses and consumers across new markets and geographies. In addition to announcing the new hires, authID.ai has promoted two company veterans to leadership positions. Having served as the Company's Chief of Staff for five years, Grace de Fries will assume the role of Senior Vice President, Communications and Investor Relations, in which she will continue to leverage her international business development, sales, marketing, and product experience. Max Umarov has been promoted to Vice President of Solution Engineering, a role in which he will help ensure top-caliber product execution and contribute to the Company's robust innovation pipeline. A member of the authID.ai team for over a decade, Umarov was instrumental in authID.ai's recently awarded patent for a biometric identity authentication routing technology that securely links various attributes of an individual user to a Primary Account Number to authenticate the user's identity. authID.ai Founder and Chief Solutions Architect Tom Szoke has been appointed Founder Emeritus. Szoke co-founded Innovation in Motion, a predecessor of authID.ai, in 2009 and has nearly three decades of product engineering, global sales and operations management experience. He successfully led the Company as Director, CEO and COO from its inception to its listing on the OTC Market, as well during the expansion of its market presence and product portfolio through strategic acquisitions in the United States, South America, and Africa.

09:02 EST Cowen Group to acquire Portico Capital Advisors - Cowen announced it has entered into a definitive agreement to acquire privately-held Portico Capital Advisors, a leading M&A advisory firm focused on the Verticalized Software, Data, and Analytics sector. The strategic acquisition positions Portico to provide the full breadth of Cowen's capital markets, advisory, and research capabilities to clients. The transaction also further accelerates Cowen's investment banking business. "Over the past 20 years, Rick Northrop, Searcy Dryden, and the Portico team have built the leading M&A advisory practice in Verticalized Software, Data, and Analytics - a critically important, fast-growing, and dynamic sector that will underpin the global economy in the decades ahead," said Larry Wieseneck, Co-President of Cowen and Company. "By combining Cowen's broad advisory and capital markets capabilities with Portico's deep sector domain experience and M&A skill set, we are delivering on our stated strategy of building a world-class, diversified banking platform that will be even better positioned to help our collective clients outperform in sectors that have strong tailwinds. We are very excited to welcome Portico's world-class team into the Cowen family." The definitive agreement has been approved by Cowen's Board of Directors and Portico's shareholders and governing bodies. All consideration is to be comprised of 75% cash and 25% stock. Other terms of the deal were not disclosed. This transaction is expected to close in the fourth quarter of 2021 and to increase Cowen's M&A advisory revenues by approximately 20% in fiscal 2022.

09:01 EST Arthur J. Gallagher acquires Park City for undisclosed amount - Arthur J. Gallagher & Co. announced the acquisition of Park City, Utah-based Real Estate Insurance Solutions. Terms of the transaction were not disclosed. Founded in 2004, Real Estate Insurance Solutions offers real estate errors & omissions insurance/cyber liability to commercial and residential real estate agents and brokers, business brokers, appraisers, home inspectors, title insurance agents, mortgage brokers, leasing agents and property managers in 32 states. Chris Nangle and his associates will remain in their current location under the direction of Kevin Garvin, head of Gallagher Affinity.

08:41 EST Eqonex names Andrew Eldon as COO, interim Chief Marketing Officer - Eqonex (EQOS) announces Andrew Eldon will assume the position of COO and interim Chief Marketing Officer. The appointment comes as the company is significantly ramping up its strategic hiring amid the exponential growth in the digital asset sector. Eldon will lead the company's efforts to unlock the significant growth potential, and strong demand across both retail and institutional client segments. Eldon joins Eqonex from HSBC (HSBC).

08:38 EST ElectraMeccanica appoints Michael Richardson to Board of Directors - ElectraMeccanica Vehicles announced the appointment of Michael Richardson to its Board of Directors, effective immediately. Michael Richardson is an automotive executive with nearly 50 years of global experience. Most recently Richardson served as Interim CEO of Dura Automotive where he was tasked with delivering multiple strategic, urgent initiatives during the global pandemic. He currently serves as an Independent Director on the Board of Directors for both Dura and Shape Corporation.

08:37 EST Phunware MaaS platform now available in AWS Marketplace - Phunware (PHUN) announced immediate availability of its Multiscreen-as-a-Service, MaaS, platform in AWS Marketplace, a digital catalog with thousands of software listings from independent software vendors that make it easy to find, test, buy, and deploy software that runs on Amazon Web Services (AMZN), or AWS. Phunware's portfolio of Smart Solutions on mobile provides access to all of the features and capabilities of the MaaS platform that any business can license to drive digital transformation through contactless digital access, room-booking, occupancy management, directories, check-in instructions, screenings, feedback tools, news, notifications, analytics, and seamless access and integration to third-party vendors and systems. "We are thrilled to work with AWS and leverage over a decade of industry experience in order to help enterprises drive digital transformation in a mobile-first world," said Randall Crowder, Chief Operating Officer at Phunware. "By adding our MaaS Platform to AWS Marketplace, customers around the world can more easily access mobile software that can tech-enable not only critical operations, but also customer and workforce engagement."

08:34 EST Bridgeline Digital partners with Optimizely to release B2B site search connector - Bridgeline Digital announced a new partnership with Optimizely, a company in the IDC Marketscape for B2B Commerce. Optimizely will use Bridgeline's Hawksearch platform to grow their B2B customer's online revenue with AI-powered product search. Hawksearch will be the first fully integrated, out-of-the-box search vendor in the Optimizely B2B Commerce admin console. The CEO of Bridgeline, Ari Kahn, says, "We are proud to be the first out-of-the-box connector for the Optimizely B2B Commerce Cloud and we expect to help Optimizely-powered web sites grow revenue."

08:33 EST Scynexis announcse results from Phase 3 VANISH-306 study - SCYNEXIS announced the peer-reviewed publication of results from its Phase 3 VANISH-306 study in the International Journal of Obstetrics and Gynaecology, BJOG. Results from the VANISH-306 study show that treatment with oral ibrexafungerp achieved superiority over placebo with a high degree of statistical significance on key study endpoints and was generally safe and well-tolerated. The VANISH development program's two pivotal Phase 3 superiority studies, VANISH-303 and VANISH-306, supported the U.S. Food and Drug Administration's, FDA, June 2021 approval of BREXAFEMME as a treatment for vulvovaginal candidiasis, also known as vaginal yeast infection. VANISH-306 was a global, multi-center, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of oral ibrexafungerp vs. placebo in women over the age of 12 with VVC. Ibrexafungerp demonstrated statistical superiority over placebo in the primary endpoint and all key secondary endpoints. At the test-of-cure Day-10 visit, patients receiving ibrexafungerp had significantly higher rates of clinical cure vs. placebo. Day-10 results also showed significantly higher rates for ibrexafungerp vs. placebo in mycological eradication, and clinical improvement. Ibrexafungerp was generally well tolerated. Reported adverse events were primarily gastrointestinal and mild to moderate in severity. In addition, at the Day-25 visit, symptom resolution was sustained and further increased with ibrexafungerp compared to placebo. Significant results were also seen in patients with C. albicans at baseline, with complete symptom resolution.

08:32 EST MDU Resources announces five-year capital investment plan of $3B - MDU Resources announced that it plans to make capital investments totaling $3B for the five-year period from 2022-26. "Our capital investment plan supports the significant opportunities we see for organic growth at all our businesses, particularly a focus on infrastructure development and grid reliability and resiliency," said David Goodin, president and CEO of MDU Resources. Acquisitions would be incremental to the company's 2022-26 outlined capital investment plan. The company will provide updates as it identifies opportunities outside the plan.

08:27 EST Ouster expands commercial presence in the Asia-Pacific to Japan/South Korea - Ouster announced the expansion of its commercial presence in the Asia-Pacific region to Japan and South Korea to further the adoption of its digital lidar. Ouster also announced the appointment of Michael Mozzhechkov as the Head of Sales in Japan, and Stephen Kim as the Head of Sales in South Korea to provide on-the-ground sales and support for its growing customer base. "Ouster's expanded presence into Japan and South Korea positions us well to capture the growing demand for digital lidar across key end markets," said Clement Kong, the Vice President of the Asia-Pacific at Ouster. "We have already seen significant traction in the industrial and robotics verticals with growing interest across our other target industries. With the appointment of commercial leadership in-country, we intend to generate new leads and increase direct customer sales, while delivering faster support to our customers and ecosystem partners."

08:19 EST Global Crossing Airlines files S-1 resale registration statement - Global Crossing Airlines Group announces that it has filed a resale registration statement on Form S-1 with the Securities and Exchange Commission to register the resale of shares of Common Stock and shares of Class B Non-Voting Common Stock issued and issuable upon the exercise of warrants issued in the Company's private placement transactions, which closed in June, 2020, January 2021 and April 2021. The Registration Statement, once effective, will subject the Company to SEC reporting requirements under the Securities Exchange Act of 1934, which the Company believes will provide it with better access to the U.S. capital markets.

08:18 EST Mayfair Gold announces drill results from Fenn-Gib Expansion Zone - Mayfair Gold announces further drill results from the Fenn-Gib Expansion Zone. The Fenn-Gib deposit, located in the Timmins region of Northeast Ontario, hosts a pit-constrained Indicated Resource of 2.08M ounces with disseminated gold mineralization striking east-west on the Pipestone Fault over 1.25 kilometers and up to 300 meters, m, wide at the west end. The Fenn-Gib Expansion Zone lies below the shallow central section of the current conceptual open pit. The drill results reported below are part of the fully funded, ongoing 80,000m drill program. Resource infill and expansion drilling is being supported by three drill rigs, and 78 holes have been completed for a total of 50,145m. Mayfair Gold President and CEO Patrick Evans commented: "Our 2021 drill campaign continues to deliver excellent results with gold mineralization in every hole. We are delighted that we have now reached the Fenn-Gib 50,000m Phase 1 infill and expansion drill program milestone earlier than scheduled. We look forward to continued positive results from the expanded 30,000m Phase 2 drill program, which we expect to complete in the second quarter of 2022." Evans added: "We are particularly excited to start our regional exploration program on both the Fenn-Gib North and South Blocks in early January. A fourth drill rig will be mobilized in mid-January for a 7,000m North Block drill program commencing at the priority Horseshoe target, which is located on the Pipestone Fault approximately 1 km to the northwest of the Fenn-Gib deposit. In addition, line cutting and ground geophysics will commence in early January on the South Block, followed by a maiden 3,000m drill program." Drill Results: The Fenn-Gib Expansion Zone drilling is supported by two of the three drill rigs and is targeting the shallow central section below the current conceptual open pit. Highlights of the newly reported mineralized intervals include: FG21-159 intersected 4.95 g/t Au over 7.40m and 0.62 g/t Au over 48.3m, including 1.06 g/t Au over 21.0m; FG21-167 intersected 0.43 g/t Au over 86.3m, including 2.05 g/t over 2.8m; FG21-171 intersected 1.10 g/t Au over 11.0m and 16.06 g/t Au over 2.0m and 0.85 g/t Au over 114.1m, including 1.22 g/t Au over 65.9m; FG21-175 intersected 0.59 g/t Au over 85.5m, including 1.69 g/t Au over 15.1m; and FG21-177 intersected 1.58 g/t Au over 26.5m and 0.81 g/t Au over 61.9m.

08:16 EST Supernus announces expiration of HSR waiting period for Adamas offer - Supernus Pharmaceuticals (SUPN) announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Supernus' proposed acquisition of Adamas Pharmaceuticals, Inc. (ADMS) expired at 11:59 p.m. on November 22, 2021. On October 21, 2021, Supernus and Adamas filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice. The expiration of the HSR Act waiting period satisfies one of the conditions to consummate the Offer. The Offer continues to be subject to the remaining conditions set forth in the Offer to Purchase and the related Letter of Transmittal. The Offer and withdrawal rights will expire at one minute following 11:59 p.m., New York time, on November 23, 2021, unless the Offer is extended or earlier terminated.

08:15 EST First Eagle Alternative Capital BDC announces redemption of notes - First Eagle Alternative Capital BDC announced that it will redeem all of its outstanding 6.125% Notes due 2023, at a redemption price of 100% of the outstanding principal amount of the 2023 Notes, plus accrued and unpaid interest to, but excluding, the date of redemption, December 21, 2021, of approximately $0.35 on each $25 principal amount if redeemed on December 21, 2021. The 2023 Notes are currently traded on the New York Stock Exchange under the symbol "FCRW".

08:14 EST Aytu BioPharma gets U.S. patent for Healight ultraviolet catheter - Aytu BioPharma announced that the United States Patent and Trademark Office, USPTO, has issued a U.S. patent for the Healight ultraviolet-A light-based respiratory catheter. U.S. Patent Number 11,179,575, titled "Internal Ultraviolet Therapy," is the first issued patent protecting the Healight investigational device and covers methods of treating a patient for an infectious condition inside the patient's body through the insertion of a UV-light-emitting delivery tube inside a respiratory cavity of the patient at specific UV-A light wavelengths. The term of this patent extends to August of 2040. "This is an important milestone in the development of the Healight medical device platform and provides for broad protection for the device platform for use as a respiratory catheter to treat infectious conditions," stated Josh Disbrow, chief executive officer of Aytu BioPharma. "Importantly, given the broad patent claim around use of the device within the full respiratory cavity, this enables potential function and clinical use of Healight beyond endotracheal application and may enable use through nasal or upper respiratory insertion. Our near-term development plan remains focused on developing Healight for severe respiratory infections - and specifically SARS-CoV-2 - affecting severely ill, ventilated patients, and we're looking forward to advancing Healight development and progressing our sham-controlled study in Barcelona, Spain."

08:14 EST Best Buy still facing higher costs on supply issues, says CEO Corie Barry - Comments taken from Q3 earnings conference call.

08:13 EST authID.ai to hold annual meeting on December 29 - authID.ai announced that its 2021 Annual Meeting of Stockholders will be held virtually on December 29, 2021, at 10:00 a.m. EST. At the meeting, proposals will be submitted to elect directors, ratify the appointment of auditors, and adopt a new Equity Incentive Plan. Stockholders will also vote for the first time on an advisory "Say-on-Pay" vote, including on the frequency of future Say-on-Pay votes. The Company is proposing the election of seven of the current eight directors, including the recently appointed Neepa Patel. Sanjay Puri will not be standing for re-election, in order to pursue other interests. Following the Annual Meeting, he will join a newly formed Company advisory board, along with other eminent business leaders to be named in due course. The Company thanks Mr. Puri for his service and support during a critical stage of the Company's development. The Company has filed its Proxy Statement with the SEC, which explains all the proposals and provides other information about the Company, and has commenced mailing the Notice of Meeting, the Proxy Statement and additional materials related to the Annual Meeting to stockholders. Stockholders who hold their shares through brokerage accounts will receive the materials via their brokers, either through the mail, or electronically depending on their communication preferences.

08:10 EST Aptevo Therapeutics announces clinical update for APVO436 trial - Aptevo Therapeutics announced a clinical update for the company's Phase 1b Expansion trial evaluating APVO436 in the treatment of acute myeloid leukemia, or AML. Preliminary data observed to date includes one complete remission. A high-risk AML patient treated in Cohort 1 with a combination of chemotherapy plus APVO436 achieved a complete remission, or CR, after one cycle of therapy. The chemotherapy regimen included the standard leukemia drugs Mitoxantrone, Etoposide, and Cytarabine. The patient tolerated treatment without evidence of overt toxicity. The overarching goal of the Phase 1b expansion phase study is to determine if APVO436 treatments can improve the quality of remission in high-risk AML patients by reducing the residual chemotherapy-resistant measurable residual disease, or MRD, burden. The quality of remission will be assessed using multiparameter flow cytometry methods for quantitative MRD assessment in a centralized laboratory. Aptevo believes that APVO436 has the potential to help AML patients achieve complete remissions without MRD and thereby reduce their risk of leukemic relapses. Aptevo also believes that the use of APVO436 for targeting MRD in AML may be associated with a very low risk of cytokine release syndrome, or CRS, as well as an increased likelihood of responses as both CRS as well as responses are inversely correlated with the leukemia burden of the patients. If successful, deepening the remission to an MRD-negative remission using this strategy could translate into an improved overall survival in AML.

08:08 EST ViaSat's mobility network in China becomes operational - In cooperation with China Satellite Communications, Viasat announced the mobility network in China, which uses Viasat's innovative in-flight connectivity, or IFC, equipment working over the Ka-band ChinaSat-16 satellite system, is now operational to meet the IFC needs of domestic and international airlines operating into and out of Chinese airspace. With the network deployment now complete, tested and operational, Viasat and China Satcom are well-positioned to meet the growing IFC demands in China-the second largest aviation market in the world, according to research from the International Air Transport Association.Viasat's agreement with partner China Satcom specifically covers commercial aviation IFC. In partnership, each company maintains its own intellectual property and will operate its equipment using a multi-layered approach to network services.

08:07 EST PPG appoints Irene Tasi as chief growth officer - PPG announced the appointment of Irene Tasi as chief growth officer, CGO, effective December 6. In this newly created role - which reports to PPG Chairman and Chief Executive Officer Michael McGarry - Tasi will lead and accelerate PPG's growth agenda with responsibility for corporate strategy, long-range planning, marketing, brand and sales excellence, digital, market-driven innovation, and new growth initiatives. She will be based at PPG's global headquarters in Pittsburgh and serve as a member of the company's Operating Committee.

08:05 EST MedAvail signs four SpotRx locations with Cano Health in California - MedAvail Holdings (MDVL) has signed an initial four clinics with Cano Health (CANO) in California. In-clinic SpotRx kiosks and courier home delivery will be available to patients at four Cano Health clinic locations in the greater Los Angeles area. SpotRx Pharmacy is the retail pharmacy brand owned and operated by MedAvail in the United States, which deploys and operates the MedAvail MedCenters. "We are thrilled to continue our collaboration with Cano Health, supporting them with their expansion into California," said Ed Kilroy, Chief Executive Officer of MedAvail. "We will be leveraging our current pharmacy infrastructure already deployed in California to service these Cano clinics." MedAvail's SpotRx Pharmacy business is primarily focused on the Medicare market and the medical clinics where they receive care. The SpotRx MedCenter allows patients to virtually consult with a pharmacist and fill their medications within clinics, eliminating the need to visit a pharmacy. SpotRx also provides patients the option to have their medications delivered to their homes free of charge. "Our partnership with SpotRx will enable us to provide a high touch pharmacy experience to our patients while also providing convenient on-site access to over-the-counter and prescription medications," said Dr. Richard Aguilar, Chief Clinical Officer of Cano Health. "We want to ensure that our patients receive high quality, affordable care and medication adherence plays an important role in population health management."

08:05 EST Kratos Defense closes sales of OpenSpace quantum, SpectralNet to 23 customers - Kratos Defense & Security Solutions announced that it closed sales of its OpenSpace quantum and OpenSpace SpectralNet products to 23 customers, supporting the satellite industry's continued movement toward dynamic, virtualized ground systems. Kratos' OpenSpace family of solutions help satellite operators move their network systems from traditional hardware to more dynamic, flexible and scalable architectures that are more responsive to service level agreements, mission goals and changing operating conditions. Sales of quantum and SpectralNet products to commercial operators remained strong in Q3, and were particularly strong to customers supporting U.S. defense and intelligence programs as well as government projects for other nations.

08:04 EST Cracker Barrel sees FY22 commodity, wage inflation in high single digits - Prior view was mid-to-high single digits. Sees FY22: Capital expenditures of approximately $120M; An effective tax rate of approximately 17%; and the opening of three new Cracker Barrel locations and 15 new Maple Street Biscuit company locations.

07:49 EST Everbridge and Howden to combine public safety tech with parametric insurance - Everbridge "announced a first-of-its-kind collaboration combining public safety technology with parametric insurance to provide a holistic approach for governments, nongovernmental organizations and charities to address climate risk and resilience.Everbridge Enters Into First-of-its-Kind Collaboration with Howden to Combine Public Safety Technology with Parametric Insurance to Address Climate Risk and Resilience By bringing together Everbridge technology with Howden's insurance expertise, response and recovery organizations are equipped to manage the entire lifecycle of a catastrophic event. Everbridge technology supports the preparation for and response to an event, while parametric insurance policies deploy much needed capital to the emergency response effort in the event of a major catastrophe. This creates a mechanism to move capital from where it is traditionally deployed, in the relief phase, into the emergency response phase of the critical event, helping to save more lives and reduce property damage before it happens." said the company.

07:45 EST Cybin gets grant for psychedelic treatment clinic at Lenox Hill Hospital - Cybin announced it has awarded a grant for the first psychedelic treatment clinic at Lenox Hill Hospital, part of Northwell Health, to serve marginalized and underserved communities on the Upper East Side of Manhattan, New York. The program aims to become one of the first hospital-based clinical sites to offer psychedelic medicine in the United States. Clinicians will also receive training in EMBARK, a transdiagnostic psychedelic psychotherapy model that can be adapted to address a range of clinical indications and populations. EMBARK is Cybin's psychotherapy model created by Dr. Alex Belser, Cybin's Chief Clinical Officer and Bill Brennan, Ph.D. . "Lenox Hill Hospital is excited by the potential of these modalities for the treatment of previously intractable conditions such as severe depression, chronic PTSD, and OCD," said David Roane, MD, Chairman of Psychiatry at Lenox Hill Hospital. "With this grant from Cybin, Lenox Hill Hospital aims to become one of the first hospital-based clinical sites offering psychedelic medicine in the country and is dedicated to addressing health inequities by prioritizing care for marginalized and underserved populations. In particular, people of color are greatly underrepresented in psychedelic research studies and our team is committed to inclusive recruitment of patients." "It's time for psychedelic medicine to climb down from the ivory tower and into the community. We are honored to support this program at Lenox Hill Hospital to start a low-cost/no-cost psychedelic-clinic for marginalized and underserved communities in New York," said Dr. Alex Belser, Chief Clinical Officer of Cybin.

07:39 EST Laurentian Bank updates timing on strategic plan, charges impacting Q4 - Laurentian Bank of Canada announced that it expects to record certain charges in its fourth quarter and fiscal 2021 results in relation to its strategic review. The Bank also announced that it will hold a virtual Investor Day on December 10, 2021, to unveil its new strategic plan, under the leadership of its new President & CEO and management team. As a result of its strategic review, the Bank expects to record certain charges to its fiscal 2021 fourth quarter earnings, estimated to reduce reported earnings by $209 million pre-tax, or $163 million after tax, and adjusted earnings by $19 million pre-tax, or $14 million after tax. Reported diluted earnings per share are expected to be impacted by approximately $3.73 and adjusted diluted earnings per share2 by $0.33. The expected charges would also impact the Bank's Common Equity Tier 1 capital ratio3 by approximately 25 basis points which is expected to remain above 10%. The expected charges are divided into four categories: Personal Banking Segment Impairment, Future of Work, Technology and Credit Provisions. Annually, the Bank conducts a goodwill impairment test. As a result of this year's test, the Bank expects to record an impairment charge on the value of its Personal Banking segment. This expected impairment reflects the recent decline in assets and deposit volumes, which, combined with the Bank's limited digital capabilities to support the ongoing changing needs of customers during the pandemic, made it challenging to retain existing customers and acquire net new ones. In addition, the Bank has also previously commented on the fact that it currently has two digital platforms, resulting in an inconsistent customer experience. In order to simplify the structure of the Bank and improve the customer experience the Bank will consolidate its two digital platforms into one. As a result, the Bank expects to record an impairment charge of approximately $93 million as follows: goodwill for an amount of $35 million, software and intangible assets for $53 million and, premises and equipment for $6 million. The pandemic has shifted the way many people work. As a result, over the past few months, the Bank has been working to refine its future of work plans, considering both customer and employee expectations. The Bank has decided to pursue and will be adopting a hybrid model, where working from home will be the first approach for all tasks that can be performed remotely. This is in line with the Bank's new strategic plan to be a more customer and people-focused Bank and is a key differentiator to attracting new talent. Given the shift to work-from-home, the Bank expects to record a charge of approximately $49 million related to a 50 percent planned reduction in leased corporate office premises in Toronto, Burlington and Montreal. This will not impact the Bank's branch footprint. In pursuing a performance-oriented culture while simplifying the organizational structure, the Bank expects to record severance charges of approximately $9 million related to 64 positions across all levels, within different entities, and are split between roles in Ontario and Quebec. In 2016, the Bank began a multi-year program to replace its core-banking system over two phases. While Phase 1 of the program has been completed and deployed, the Bank reassessed, as part of its strategic review, the second phase of the project, which mostly included accounts and products from the retail branch network. Given the rapid evolution and advancement of technology, the Bank is looking to leverage new capabilities through partnerships to deliver products and services in a faster, more efficient way to market, while improving the overall customer experience. As a result, the Bank has made the decision to cease Phase 2 of the program and expects to record a charge of approximately $38 million. As part of the overall strategic review, the Bank reassessed the investment loan product design and adjusted its credit standards resulting in an acceleration of remediation of a portion of the investment loan portfolio. As a result, allowances and provisions for credit losses are expected to increase by approximately $19 million in the fourth quarter of 2021. This anticipated charge will not be designated as an adjusting item to calculate the Bank's adjusted results and ratios. The expected impact on expenses on a pre-tax basis, stemming from these decisions is estimated to generate approximately $4 million of cost reductions for the fourth quarter of 2021 and $20 million of ongoing cost reductions starting in 2022. These are mainly as a result of lower amortization charges and lower rent expenses.

07:36 EST Dick's Sporting reports total inventory increased 7.3% at the end of Q3 - Compared to the end of the third quarter of 2020.

07:35 EST Dick's Sporting CEO says Q4 'off to a strong start' - "Our strategies continue to work as we reimagine the athlete experience in our core business and with new concepts. As we said before, we believe this will be the most transformational year in our history, and we expect to continue this transformation into 2022. I couldn't be more excited about the future of DICK'S Sporting Goods," said Ed Stack, Executive Chairman. "We are extremely pleased to announce a record third quarter in which we delivered significant sales and earnings growth over both last year and 2019. Consumer demand remained strong, and our differentiated product assortment continued to drive exceptional sales and merchandise margin momentum. I'd like to thank all of our teammates for their hard work and commitment to DICK'S Sporting Goods, which helped make this performance possible," said Lauren Hobart, President and CEO. "Our fourth quarter is off to a strong start, and we are pleased to increase our full year outlook for the third time this year. Looking ahead, we remain very confident in the longer-term prospects of our business."

07:32 EST Minim launches new e-commerce site MotorolaNetwork.com - Minim unveils MotorolaNetwork.com, an e-commerce site with deals for consumers and broadband service providers. With this launch, the company is also releasing the value-packed Motorola AC2200 Smart Router at $99.99, bringing high-performance WiFi and the motosync app to apartments and small homes. Starting today on MotorolaNetwork.com, the Motorola AC2200 Smart Router makes its debut, offering: WiFi coverage up to 2,000 square feet; Connection management of up to 100 devices; motosync mobile app with advanced security, parental controls, data tracking; and 2-year warranty "Our priority is to make it easy for customers to secure and personalize home networks with motosync, powered by Minim," said Nicole Zheng, President and CMO at Minim. "While we are focused on continued sales growth in leading retailers and online marketplaces, we wanted to offer a single destination for making a strong connection with Motorola networking solutions. Now, both consumers and ISP partners can find the latest products and software features on MotorolaNetwork.com and sign up for promotions. We're just getting started."

07:18 EST Manscaped to become public through Bright Lights Acquisition combination - Manscaped and Bright Lights Acquisition (BLTS) announced they have entered into a definitive business combination agreement that will result in Manscaped becoming a public company. Upon closing of the transaction, the combined company will be renamed Manscaped and expects to apply to be listed on the Nasdaq under the new ticker symbol (MANS). The combined company will be led by Paul Tran, founder and CEO of Manscaped. The business combination implies an enterprise valuation for Manscaped of $1B, or approximately 2.6x 2022 revenue. The transaction will provide $305M in gross proceeds to the company, assuming no redemption by Bright Lights shareholders, including a $75M fully committed common stock PIPE at $9.20 per share. All of Manscaped's shareholders will roll their equity holdings into the newly public company. After closing, assuming no redemptions, the company expects to have $235M on the balance sheet and no debt. The boards of directors of both Manscaped and Bright Lights have unanimously approved the transaction. The transaction will require the approval of the shareholders of both Manscaped and Bright Lights, and is subject to other customary closing conditions, including the receipt of certain regulatory approvals. The transaction is expected to close in Q1 of 2022.

07:15 EST Garmi announces transfer of listing to the NYSE - Garmin announced that it will transfer the listing of its shares from the Nasdaq National Market to the New York Stock Exchange . Garmin expects to commence trading as a NYSE-listed company at market open on December 7. under its ticker symbol "GRMN." Garmin will continue to trade its shares on the Nasdaq until the market close on December 6. "Garmin is pleased to join the NYSE alongside many of the world's most well-established and regarded companies," said Cliff Pemble, president and CEO of Garmin. "Garmin is uniquely positioned as both a highly respected consumer brand and a strong industrial player. We believe this move complements our strong brand and will provide meaningful and long-term value for our shareholders."

07:10 EST Wingstop plans to develop traditional locations and ghost kitchens in Manhattan - Wingstop announced plans in July to develop the Manhattan, NY area in a company-owned strategy that includes an asset mix of traditional locations and ghost kitchens, with more than 20 upcoming openings over the course of three years. The brand believes its entrance into Manhattan presents an opportunity to invest capital and deliver great returns for shareholders by participating in Wingstop's best-in-class unit economics.

07:08 EST BeiGene closes on property for new U.S. manufacturing and clinical R&D center - BeiGene announced that it has purchased a 42-acre site at the Princeton West Innovation Campus in Hopewell, N.J. to house a new state-of-the-art manufacturing campus and clinical R&D center. As a key part of BeiGene's continued growth, the company is investing in U.S. manufacturing to further expand and diversify its global supply chain and build new manufacturing capabilities for its deep pipeline of biologic and drug candidates. Subject to finalizing the development plans, BeiGene expects to invest several hundred million dollars in the initial phase of construction, in addition to the acquisition of the property, for the state-of-the-art facility that is expected to include up to approximately 400,000 square feet of dedicated commercial-stage biologic pharmaceutical manufacturing, including up to 16,000 liters of biologics capacity, along with clinical R&D and office space. Construction of the initial phase is expected to commence in 2022 and be completed in late-2023 or in 2024. In addition, the property has more than one million square feet of developable real estate for potential future expansion. "With this property acquisition, we plan to establish a flagship manufacturing and clinical R&D center in the U.S. to diversify our global supply chain. We are proud to take this next step in our journey to advance impactful treatments and make them more accessible to patients around the world," said John V. Oyler, Co-Founder, Chairman, and CEO of BeiGene. "We have already begun hiring additional colleagues from the deep talent pool in New Jersey and look forward to serving as a member of the thriving Princeton-Hopewell business community."

07:06 EST Aligos Therapeutics and Vipergen sign drug discovery agreement - Vipergen announced the signing of a multi-target drug discovery agreement with Aligos Therapeutics. Under the terms of the agreement, Vipergen will apply its high-fidelity DEL technology platforms to identify novel small-molecule compounds that bind to selected Aligos protein targets. Aligos will select hits for development into novel therapeutics for viral and liver diseases. Aligos will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed.

07:05 EST FTFT UK opens new office in London - Future FinTech Group announced that its new subsidiary, FTFT UK, held an inauguration ceremony on November 19 for the opening of its new office in London, during which FTFT UK announced that it has entered the beta testing phase for its mobile financial app which will enable customers to engage in a comprehensive suite of e-wallet activities. Representatives from the local business and financial sectors, including executives of MasterCard, JP Morgan Chase, China Mobile and Bank of China attended the event.

07:04 EST J.M. Smucker CEO says Q2 results 'exceeded our expectations' - "Our second quarter results, including comparable net sales growth of 8 percent, exceeded our expectations and demonstrated sustained momentum for our business and strong execution by our talented employees in what remains a dynamic operating environment," said Mark Smucker, President and CEO. "We delivered robust organic top-line growth across each of our segments, reflecting consumers' continued desire for our brands and the successful implementation of initial pricing actions. We are pleased with our ability to increase our net sales and adjusted earnings per share expectations for the fiscal year despite increasing cost inflation and continued supply chain disruption. We remain confident that the actions we are taking to execute our strategy are positioning us to deliver sustainable growth and create shareholder value over the long term."

07:02 EST Compass Pathways granted fifth US patent for crystalline psilocybin - COMPASS Pathways announced that it has been granted its fifth patent by the US Patent and Trademark Office, USPTO. This is COMPASS's 10th patent overall, with five now granted in the US, two in the UK, one in Germany and two in Hong Kong. The new patent, US Patent No 11,180,517, covers methods of treating treatment-resistant depression, TRD, with crystalline psilocybin as well as with oral dosage forms of crystalline psilocybin with an excipient. Crystalline psilocybin is used in COMP360, COMPASS's synthesised psilocybin formulation being developed for psilocybin therapy in TRD. George Goldsmith, CEO and Co-founder, COMPASS Pathways, said: "This 10th patent is a strong testament to our innovation. Patents enable us to continue to do the highest quality clinical research so we can work to bring therapies to patients who are suffering with serious mental health challenges and have few options."

06:53 EST Tricon Residential provides update on build-to-rent community pipeline - Tricon Residential provided an update on its active build-to-rent community pipeline, which has now expanded to over 3,000 rental units in 23 new home communities across the U.S. Sun Belt. The communities are under development or under contract to be developed within Tricon's existing single-family rental investment vehicles THPAS-JV1 and Homebuilder Direct JV, and are being built by a number of national and regional homebuilders including four of the top 25 largest homebuilders in the United States. "COVID-19 has cast light on the shortage of affordable housing options across the U.S.," said Gary Berman, president and CEO of Tricon Residential. "At Tricon, we are committed to expanding the supply of accessible, high-quality housing for families who are seeking a single-family home and prefer the convenience and flexibility of a rental lifestyle. We are also focused on building sustainable communities that enrich the lives of our residents and the local neighborhoods they live in, which is central to our corporate strategy and our Environmental, Social and Governance ("ESG") priorities. Our build-to-rent pipeline makes a positive contribution to alleviating America's housing shortage, while stimulating local economic growth and catering to the needs of modern residents."

06:51 EST Burlington Stores CEO says 'clearly we are taking significant market share' - Michael O'Sullivan, CEO, stated, "We are very pleased with our third quarter results. We continued to demonstrate our ability to chase the business and deliver great value to our customers. With Total Sales up 30% in Q3, and up 32% YTD, clearly we are taking significant market share." O'Sullivan went on, "As predicted, freight and supply chain headwinds pressured margins in Q3. We fully expect these headwinds to moderate over time and, as they do, this should generate very attractive off-price buying opportunities as well as significantly lower expenses. As the economy moves into a more inflationary environment, we think that shoppers will be even more attracted to our great values. Our value differentiation vs. most other retailers has grown this year, as they have raised realized prices. If these higher realized prices are sustained then we believe that in the coming quarters we will have the opportunity to drive additional sales, to raise retails, or to do both. This year we have been very excited about the performance of our new stores, especially our smaller prototype. Based on this performance and on the tremendous market share opportunity that we see ahead of us, we have decided to accelerate the pace of our new store opening program."

06:48 EST Burlington Stores lowers FY21 CapEx view to $425M from $510M - The company now expects to open 101 new stores, while relocating or closing 24 stores, for a total of 77 net new stores in Fiscal 2021; Depreciation & amortization, exclusive of favorable lease costs, is now expected to be approximately $250M; Interest expense is now expected to be approximately $68M; and the effective tax rate is now expected to be approximately 23%.

06:32 EST Quarterhill subsidiary acquires semiconductor technologies patent portfolio - WiLAN, a Quarterhill company, announced that one of WiLAN's wholly-owned subsidiaries has acquired a patent portfolio from a publicly-traded semiconductor technologies company. The acquired patents relate to wired connectivity functionality, including various USB-C technologies used in a wide range of applications such as desktop and laptop computers, tablets, mobile phones, gaming consoles, and smart TVs. All other terms of the transaction are confidential.

06:03 EST Aadi Bioscience announces FDA approval of Fyarro as treatment for PEComa - Aadi Bioscience announced that the FDA has approved FYARRO, or sirolimus protein-bound particles for injectable suspension, for intravenous use for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor, or PEComa. FYARRO is the first and only FDA-approved treatment for advanced malignant PEComa in adults. In the Phase 2 registrational AMPECT trial the overall response rate as assessed by independent review was 39%, with 2 patients achieving a Complete Response after prolonged follow up. The median duration of response has not been reached with a median follow-up of 36 months, and a range of 5.6 to 55.5+ months and ongoing.

05:17 EST Cnooc commences production of Lufeng oil fields project - Cnooc announced the commencement of production of Lufeng oil fields regional development project. The Lufeng oil fields is located in Eastern South China Sea and mainly include Lufeng 14-4 oil field, Lufeng 14-8 oil field, Lufeng 15-1 oil field and Lufeng 22-1 oil field, with an average water depth of about 140-330 meters. The main production facilities include 2 drilling production platforms and one subsea production system. A total of 35 development wells are planned to be put into production, including 26 production wells and nine water injection wells. The project is expected to achieve its peak production of approximately 46,000 barrels of crude oil per day in 2023. Cnooc Limited owns 100% interest in the Lufeng oil fields regional development project.